ANIC.L

Agronomics Limited
Agronomics Limited - Portfolio Company Presentation Series – Formo Bio
16th September 2024, 11:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3471E
Agronomics Limited
16 September 2024
 

RNS Reach

16th September 2024

Agronomics Limited

("Agronomics" or the "Company")

Portfolio Company Presentation Series - Formo Bio GmbH

Agronomics (LSE: ANIC), a leading listed company in the field of cellular agriculture, is pleased to announce that it will be hosting the fourth presentation in its Capital Markets portfolio series.

The Agronomics' Capital Markets Investor Presentation Series comprises individual presentations from industry-leading companies in the cell culture and precision fermentation sector within the Agronomics portfolio. For each presentation, the portfolio company's management team will provide in-depth insights into the purpose, market demand, technical milestones, and growth strategy of the company, together with a Question & Answer session at the end of the presentation. Agronomics expects to hold, on average, a presentation every eight weeks.

The presentation will include the senior management team at Formo Bio GmbH ("Formo") on 26  September 2024 at 15:00 BST. Attendees are able to register for the event using the following link: https://us02web.zoom.us/webinar/register/WN_xiVZVFEnTnaQMeb6rIAjmg#/registration.

After registering, attendees will receive a confirmation email containing information about joining the webinar.

Formo is an innovative European fermentation startup that is redefining the future of cheese. Founded in 2019, with locations in Berlin and Frankfurt, Formo develops animal-free alternatives that combine taste and sustainability. Using state-of-the-art fermentation technology, Formo creates cheese alternatives that taste great and contribute positively to the environment. Learn more at https://formo.bio/.

Formo recently announced that it has successfully raised US$ 61 million in its Series B funding round which will help the company achieve key milestones, including international expansion, diversifying the product range, driving revenue growth and achieving net profitability by 2027. Formo will also invest in its technology platform to accelerate the commercialisation of animal-free casein products, which will expand the portfolio to include hard cheeses, opening further opportunities in the market.

In addition to the new financing, Formo announced that its first two cheese products Frischhain and Camembritz, are now available at over 2,000 REWE, BILLA and METRO stores across Germany and Austria.

About Agronomics

Agronomics is a leading London-listed company focussing on investment opportunities within the field of cellular agriculture. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

For further information please contact:

Agronomics Limited

Beaumont Cornish Limited

Canaccord Genuity Limited

Cavendish Capital Markets Limited

Peterhouse Capital Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Jim Mellon

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Pardoe

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Charlie Combe

Lucy Williams

Charles Goodfellow

Bob Huxford

Anthony Hughes

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

Nominated Adviser

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPUWGBUPCGUQ]]>
TwitterFacebookLinkedIn